Nathan J Robison MD

Pediatric Hematology & Oncology•Los Angeles, CA

Pediatric Neuro-Oncology

Assistant Professor

Join to View Full Profile

4650 W Sunset BlvdLos Angeles, CA 90027
Phone+1 323-361-3550
Fax+1 323-361-8052

Education & Training

Brigham and Women's Hospital/Dana-Farber Cancer Institute/Harvard Medical SchoolFellowship, Pediatric Neuro-Oncology, 2009 - 2010
Children's Hospital Los AngelesFellowship, Pediatric Hematology/Oncology, 2006 - 2009
Children's Hospital Los AngelesResidency, Pediatrics, 2002 - 2005
Keck School of Medicine of the University of Southern CaliforniaClass of 2002

Certifications & Licensure

CA State Medical License 2004 - 2026
MA State Medical License 2009 - 2014
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG) Start of enrollment: 2011 Sep 01
Terminated
Phase 2
MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1 Start of enrollment: 2014 Jun 01
Completed
Phase 2
A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration Start of enrollment: 2020 Jan 17
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Roles: Contact, Principal Investigator
Phase I Study of APX005M in Pediatric Central Nervous System Tumors Start of enrollment: 2018 Mar 01
ACTIVE_NOT_RECRUITING
PHASE1
Roles: Contact, Principal Investigator
Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG Start of enrollment: 2017 Apr 04
ACTIVE_NOT_RECRUITING
NA
Roles: Contact, Principal Investigator
Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery Start of enrollment: 2019 Jul 25
RECRUITING
PHASE1, PHASE2
Roles: Contact
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma Start of enrollment: 2022 Jul 01
RECRUITING
PHASE1
Roles: Principal Investigator, Contact
Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered
NO_LONGER_AVAILABLE
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

A Phase 2 PBTC Study of Selumetinib for Recurrent/Progressive Pediatric Low-Grade Glioma: Strata 2, 5, and 6 with Long-term Outcomes on Strata 1, 3, and 4.
Jason Fangusaro, Arzu Onar-Thomas, Tina Young Poussaint, Shelly Lensing, Azra H Ligon
Neuro-Oncology. 2025-04-17
Lack of classical astroblastoma features in pediatric MN1::BEND2-fused brain tumors.
Nicholas Chapman, Mohammed Iqbal, Adam D Walker, Debra Hawes, Tom Belle Davidson
Brain Pathology. 2025-03-01
2 citations
ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma.
Christopher L Moertel, Angela C Hirbe, Hans H Shuhaiber, Kevin Bielamowicz, Alpa Sidhu
Journal of Clinical Oncology. 2025-02-20

Press Mentions

Six Things to Look for in a Pediatric OncologistDecember 18th, 2024
Gateway for Cancer Research Announces Completion of Phase I Clinical Trial Using “Tumor Paint” in Pediatric Brain Cancer SurgeryApril 24th, 2018